The ESMO TAT Asia 2025 programme is online!
Learning objectives
In the Keynote lectures, Educational sessions, Special sessions with Industry, Scientific sessions and Poster exhibition, attendees will be able to update their knowledge on:
- Innovation in methodologies for early phase drug development
- Novel concepts in preclinical modelling
- New imaging technologies
- Breakthroughs in novel kinase inhibitors, oral immunotherapies, next-generation macromolecules and cell-based therapies
- Methodological and regulatory challenges in the development of new agents
- Multi-stakeholder insights from the oncology and biotechnology industries
Audience
The ESMO TAT Asia programme will be of interest to persons working in academia, industry, and regulatory agencies engaged in the discovery and early clinical development of novel anticancer therapies, including, but not limited to, preclinical scientists, clinicians, methodological experts, legal and regulatory affairs specialists, industry investigators and executives, other professionals active in anticancer drug development, and patient advocates. The programme will be of educational value to oncologists, haematologists, pathologists, and organ system specialists, with a unique osmosis between academia and industry.
Accreditation
ESMO-MORA: The ESMO TAT Asia Congress 2025 programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.